Peptide receptor radioisotope therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): From literature to practice

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs

SPECT/CT Imaging in a Rabbit Model of Emphysema Reveals Ongoing Apoptosis In Vivo

NETTER-1 Phase III: Progression-Free Survival, Radiographic Response, and Preliminary Overall Survival Results in Patients with Midgut Neuroendocrine Tumors Treated with 177-Lu-Dotatate

Single photon emission computed tomography imaging of cerebral blood flow, blood-brain barrier disruption, and apoptosis time course after focal cerebral ischemia in rats

177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: Results of the phase III NETTER-1 trial